PTPI - Petros Pharmaceuticals, Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

PTPI

PETROS PHARMACEUTICALS, INC.

OTC

$0.00

▲ UP 14.29% (0.00)

KEY STATISTICS

Market Cap$169.49 K

52w High$0.03

52w Low$0.00

Dividend Yield—

Frequency—

P/E—

Volume205.18K

Shares Out.42.37M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Fady Boctor

COMPENSATION 2026

Salary$186,630

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$66,070

Total$252,700

ABOUT

SECTOR

Healthcare

WENT PUBLIC

December 2, 2020

METHOD OF GOING PUBLIC

Reverse Merger

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateDec 2, 2026

DayWednesday

Rev. Est.—

DEC

WED

SPLIT RECORD

DATE	TYPE	RATIO
2025-05-01	Reverse	1:25
2022-12-01	Reverse	1:10

PRICE

$0.00 ▲ UP 14.29% (+$0.00)

OVERLAYS

About Petros Pharmaceuticals, Inc.

https://www.petrospharma.com ↗

Petros Pharmaceuticals, based in New York, develops and commercializes men's health therapeutics, including ED treatments like Stendra and vacuum devices, and is working on H100 for Peyronie's disease.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT PETROS PHARMACEUTICALS, INC. IS KNOWN FOR

STENDRA® (avanafil)

STENDRA® is Petros Pharmaceuticals' flagship prescription PDE5 inhibitor for erectile dysfunction, with efforts underway to obtain FDA approval for OTC availability.